Abbott today introduced Alinity, a unified platform that links immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening, and molecular diagnostics across a health system.
Each diagnostic platform contains universal interfaces with the same software and hardware. The systems were designed with the ability to run any test at any time, produce faster results and minimize human error.
"With our unified family of testing instruments, we'll be able to offer more efficiency, flexibility and confidence to health systems and better help doctors and nurses get the results they need to improve decision-making and patient care," said Brian Blaser, executive vice president of diagnostic products for Abbott Park, Ill.-based Abbott.
The company expects launches of Alinity to start later this year and continue into 2017.
More articles on supply chain:
IU Health breaks ground on $9M integrated supply center
Premier closes dose tracking agreement with Sectra
Medline to open new distribution center in Fla.